Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929864 · ClinicalTrials.gov registry record · Phase 3
Abatacept Versus Adalimumab Head-to-Head
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 869
- Enrollment target
NCT00929864: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00929864 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 869 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00929864, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 869 participants
- Enrollment target
Study Summary
The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive
Primary Outcome
Proportion(%)=number of participants meeting criteria (n) divided by number of participants who received drug (N). The ACR score indicates degree of improvement in a patient's rheumatoid arthritis (RA), based on guidelines set forth by the ACR and represents a percentage. To qualify a ACR20 score, patient must have \>=20% fewer tender joints and \>=20% fewer swollen joints and show 20% improvement from baseline in at least 3 of: patient overall assessment of his/her RA, physician global assessme
Interventions
- DRUG Abatacept
- DRUG Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 869 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
What the finished NCT00929864 record still lists
NCT00929864 is an interventional study that assigns participants to a tested intervention. The registered 869 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 2 interventions - of which Abatacept is the first listed.
NCT00929864 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00929864 about?
NCT00929864 is a clinical study titled "Abatacept Versus Adalimumab Head-to-Head". The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive
What is the current status of trial NCT00929864?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 869 participants. The study started on 2009-10. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00929864?
The interventions under investigation include: Abatacept (DRUG), Adalimumab (DRUG).
Who is sponsoring clinical trial NCT00929864?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00929864's enrollment target sits among peer trials
869 374th of 2000 higher than 1,626 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia